Dendrite to Sponsor CRM for Pharmaceuticals Conference in London, UK.
MORRISTOWN, NJ--(BUSINESS WIRE)--June 22, 2001
Company's Senior Vice President and Chief Technology Officer to Discuss New Pharmaceutical CRM Solutions During June 25-26 Business Intelligence Conference
Dendrite (NASDAQ/NMS: DRTE), the visionary innovator in global pharmaceutical technology, today announced that it will sponsor the Customer Relationship Management for Pharmaceuticals conference in London, UK June 25-26, 2001.
On June 25 at 5:30 p.m., Marc Kustoff, Dendrite's Senior Vice President and Chief Technology Officer, will deliver a presentation titled "A Pharmaceutical CRM Vision." He will discuss the changing nature of pharmaceutical CRM, the influence of technology on pharmaceutical sales and marketing efforts, and Dendrite's new CRM strategy.
Mr. Kustoff will also review the implications of Dendrite's recently announced strategic partnership with Oracle Corp. The two companies will integrate Oracle's E-Business Suite and Dendrite's WebForce(TM) Sales Force Effectiveness application to market the first fully integrated CRM solution, with unparalleled business intelligence, specifically for pharmaceutical companies.
Dendrite (NASDAQ/NMS:DRTE), the visionary innovator in global pharmaceutical technology, helps clients strategically manage their customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. For more information, visit the company's website at www.dendrite.com.
About Business Intelligence
Business Intelligence delivers independent, authoritative advice on emerging business trends and practices including CRM, Supply Chain, Data Warehousing, Balanced Scorecard, Business Intelligence, Human Resources, and Knowledge Management, presenting its findings in the form of conferences, exhibitions, publishing, training courses, and web communities. For more information, visit the company's website at www.business-intelligence.co.uk.
Note: Dendrite is a registered trademark of Dendrite International, Inc.
The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 22, 2001|
|Previous Article:||Scottish Power PLC Announces Corporate Calendar.|
|Next Article:||Ikimbo Names Todd Bramblett Senior Vice President of Global Services.|